Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease

COVID-19 Clinical Trial

Official title:

A Randomized, Double-blind, Parallel, Placebo-control Study to Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06175468
• Other study ID #: CMUH112-REC2-154
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: December 15, 2023
• Est. completion date: August 2024

Study information

• Verified date: December 2023
• Source: China Medical University Hospital
• Contact: Chia-Ing Li, PhD
• Phone: + 886-4-22052121
• Email: 006446[@]tool.caaumed.org.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"Formosa 1-Breath Free (NRICM101) " has been widely known in Taiwan to treat COVID-19. However, there is no phase III pivotal clinical trial of "Formosa 1-Breath Free (NRICM101) " . In order to obtain scientific, standardized, and comparable clinical results, the study will be implemented to evaluate the efficacy of safety of "Formosa 1-Breath Free (NRICM101) ".

The objective of the study was used the product which be provided by Tian-I Pharmaceutical Co. Ltd. to evaluate the efficacy and safety of the subjects with the symptoms of COVID-19 or Influenza-like after taking "Formosa 1-Breath Free (NRICM101) ".

This study is a randomized, double-blind, parallel controlled clinical trial. The study consisted of 3 cycles: screening period, treatment period (5 days) and follow-up period. The treatment of this study is divided into two groups: The test drug is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day；The control drug is the placebo (dummy) 5g/bag, 3 times a day. The sample size in the study is at least 150 people who can be evaluated, and the dropout rate of the test is 10-15%. The estimated sample size is around 170 people. After signing the ICF, vital signs (sitting blood pressure, pulse rate, SpO2, respiratory rate and body temperature), physical examination, chest X-ray, and laboratory test will be checked in screening period. Only subjects with clinically acceptable and following the inclusion and exclusion criteria will eligible to enroll in this study. Compliance will be assured by administration of the study drug under the supervision of the investigator or his deputy. Subjects will be free to withdraw at any time without stating any reason. Data will be analyzed from those subjects who complete the entire study; however, the case report forms and the final study report should include reasons for withdrawals and any necessary treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 170
• Est. completion date: August 2024
• Est. primary completion date: April 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Subjects who meet the criteria guideline in the "Seasonal Influenza Prevention and Control Manual" recommended by the Taiwan Centers for Disease Control, or are determined by the investigator to have mild symptoms of COVID-19, including fever, sore throat, cough, and fatigue.

• Subjects who have had a fever (body temperature =37.5°C and =39°C) before their initial dose.

• Throat pain intensity score >30 points during the screening period.

• Cough severity score >3 points during the screening period.

• Fatigue level score >30 points during the screening period.

• Able to perform activities of daily living and aged 20 weeks or older.

• Duration of illness =24 hours.

• Obtained informed consent from the subject and signed the informed consent form.

Exclusion Criteria:

• Subject has used other medications for this condition (including cold medicine, antibiotics, antiviral drugs, and similar traditional Chinese medicines) within the 24 hours prior to screening, or is determined by the investigator to require the use of antibiotics or COVID-19 anti-virus drugs.

• Subject has used corticosteroids or NSAIDs for an extended period within the four weeks prior to screening.

• Subject has had poorly controlled chronic diseases in the past five years, including cardiovascular, respiratory, gastrointestinal, immune-related conditions, or mental health disorders (as determined by the investigator).

• Subject has had chronic bronchitis, streptococcal pharyngitis, herpetic pharyngitis, or pneumonia within the past two years or at the time of screening (as determined by the investigator).

• Subject is allergic to the investigational drug or its components.

• Women who are pregnant, breastfeeding, or planning to become pregnant.

• Subject has participated in other drug clinical trials within the 90 days prior to screening.

• The investigator evaluates the subject unsuitable for inclusion in the study.

Related Conditions & MeSH terms

• COVID-19
• Influenza Viral Infections
• Influenza, Human
• Virus Diseases

Intervention

Drug:
• Formosa 1-Breath Free (NRICM101)
After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.
• Placebo control drug
After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung

Sponsors (4)

Lead Sponsor	Collaborator
China Medical University Hospital	China Medical University, China, Qualitix Clinical Research Co., Ltd., Tian-I Pharmaceutical,. Co. Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sore Throat Visual Analogue Scale (VAS)	Assessing the improvement in sore throat in subjects with symptoms of COVID-19 or influenza-like symptoms. Using the Visual Analogue Scale (VAS) with a range of 0-100, the absolute value of the baseline change in pain intensity is calculated as the Sum of Pain Intensity Differences (SPID), serving as an indicator of the degree of therapeutic improvement.	Sore throat will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days
Secondary	Cough Cough Symptom Score (CSS)	Evaluate the improvement in the severity of cough in subjects with symptoms of COVID-19 or influenza-like symptoms. Use the Cough Symptom Score (CSS) to calculate the baseline change as an indicator of the degree of therapeutic improvement.	Cough will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days
Secondary	Fatigue Visual Analogue Scale (VAS)	Assess the improvement in fatigue in subjects with symptoms of COVID-19 or influenza-like symptoms. Use the Visual Analogue Scale (VAS) with a range of 0-100 as an indicator to calculate the absolute value of baseline change as a measure of therapeutic improvement.	Fatigue will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days
Secondary	Nasal Symptoms Total Nasal Symptom Score (TNSS)	Assess the improvement in nasal symptoms in subjects with symptoms of COVID-19 or influenza-like symptoms. Use total nasal symptom score (TNSS) with a range of 0-100 as an indicator to calculate the absolute value of baseline change as a measure of therapeutic improvement.	Nasal symptoms will be recorded prior to the first dose, one hour after the first dose every morning, and one hour after the last dose for 5 days
Secondary	Fever Level	Evaluate the improvement in fever in subjects with symptoms of COVID-19 or influenza-like symptoms. Calculate the time (in hours) from the first dose of medication to the first onset of temperature relief, as well as the time from complete relief to a normal value. Temperature relief is defined as a temperature below 37.5°C, and the time for final complete relief is the point in time after the last occurrence of fever when the temperature returns to normal. Additionally, calculate the baseline change in temperature for each measurement as an indicator of therapeutic improvement.	Fever measurements will be taken before the first dose, and one hour after each dose for 5 days
Secondary	Safety evaluation	Evaluate the safety of subjects with symptoms of COVID-19 or influenza-like symptoms after administration of the medication to the end of study	Record the adverse event form the baseline to the end of study and follow up to 14 days
Secondary	Traditional Chinese Medicine (TCM) Syndrome Severity	Evaluate the improvement in Traditional Chinese Medicine (TCM) syndrome severity in subjects with symptoms of COVID-19 or influenza-like symptoms. Assess the TCM syndrome efficacy using two TCM syndrome scoring scales for primary and secondary symptoms, respectively. Calculate the total scores for the primary symptom scale, the total scores for the secondary symptom scale, and the total syndrome scores (including both primary and secondary symptoms) as indicators of baseline change in absolute values.	The Traditional Chinese Medicine (TCM) syndrome will be assessed by the physician during the screening period and at the final follow-up visit up to 14 days.